News Mixed outcomes for pharma in big week for FDA adcomms There was good news for Johnson & Johnson at this week's ODAC meetings, but not for Roche, UroGen, and Pfizer.
News UroGen’s urothelial cancer drug bags FDA approval The FDA has approved UroGen’s Jelmyto (mitomycin gel) as the first therapy to treat low-grade upper tract urothelial cancer (UTUC).
News UroGen appoints former Novartis cancer chief Barrett as CEO Novartis’ former oncology CEO Liz Barrett has left to join a little known biotech, UroGen, to help bring its potential urothelial cancer drug to market.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.